ThermoGenesis Corp. (KOOL) today announced a strategic
reorganization initiative designed to better align resources with its expected
cord blood revenue streams, increase its internal clinical resource capabilities
and provide greater focus on new application development to improve the
Company's market competitiveness and to speed AXP(R) AutoXpress(R) Platform
(AXP) adoption in developed and emerging markets.
The Company expects these changes will enable it to generate
cash from its cord blood business in the coming two to three quarters in
addition to realigning its professional resources to support its rapid
expansion into the regenerative medicine space. "One of our primary
objectives is to continue to invest in our AXP Platform and clinical resources
needed to further expand the system's clinical intelligence and technological
functionality. In this way, we can better meet the evolving cell processing
needs of our cord blood customers and expand its use into our vascular and
orthopedic cell therapy initiatives," said Matthew Plavan, Chief Executive
Officer of ThermoGenesis. Read more.
No comments:
Post a Comment